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A bs tr ac t
Background
We previously reported that integrating antiretroviral therapy (ART) with tuberculosis 
treatment reduces mortality. However, the timing for the initiation of ART during 
tuberculosis treatment remains unresolved.
Methods
We conducted a three-group, open-label, randomized, controlled trial in South Africa 
involving 642 ambulatory patients, all with tuberculosis (confirmed by a positive 
sputum smear for acid-fast bacilli), human immunodeficiency virus infection, and 
a CD4+ T-cell count of less than 500 per cubic millimeter. Findings in the earlier-
ART group (ART initiated within 4 weeks after the start of tuberculosis treatment, 
214 patients) and later-ART group (ART initiated during the first 4 weeks of the con-
tinuation phase of tuberculosis treatment, 215 patients) are presented here.
Results
At baseline, the median CD4+ T-cell count was 150 per cubic millimeter, and the 
median viral load was 161,000 copies per milliliter, with no significant differences 
between the two groups. The incidence rate of the acquired immunodeficiency syn-
drome (AIDS) or death was 6.9 cases per 100 person-years in the earlier-ART group 
(18 cases) as compared with 7.8 per 100 person-years in the later-ART group (19 cases) 
(incidence-rate ratio, 0.89; 95% confidence interval [CI], 0.44 to 1.79; P = 0.73). How-
ever, among patients with CD4+ T-cell counts of less than 50 per cubic millimeter, the 
incidence rates of AIDS or death were 8.5 and 26.3 cases per 100 person-years, respec-
tively (incidence-rate ratio, 0.32; 95% CI, 0.07 to 1.13; P = 0.06). The incidence rates of 
the immune reconstitution inflammatory syndrome (IRIS) were 20.1 and 7.7 cases per 
100 person-years, respectively (incidence-rate ratio, 2.62; 95% CI, 1.48 to 4.82; P<0.001). 
Adverse events requiring a switching of antiretroviral drugs occurred in 10 patients in 
the earlier-ART group and 1 patient in the later-ART group (P = 0.006).
Conclusions
Early initiation of ART in patients with CD4+ T-cell counts of less than 50 per cubic 
millimeter increased AIDS-free survival. Deferral of the initiation of ART to the first 
4 weeks of the continuation phase of tuberculosis therapy in those with higher CD4+ 
T-cell counts reduced the risks of IRIS and other adverse events related to ART with-
out increasing the risk of AIDS or death. (Funded by the U.S. President’s Emergency 
Plan for AIDS Relief and others; SAPIT ClinicalTrials.gov number, NCT00398996.)
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I
n patients who have infection with 
the human immunodeficiency virus (HIV) and 
tuberculosis, antiretroviral therapy (ART) may 
be initiated at the same time as or soon after the 
initiation of tuberculosis treatment. However, an-
tiretroviral agents are often deferred until after the 
intensive phase of tuberculosis treatment because 
of concern about the immune reconstitution in-
flammatory syndrome (IRIS),1,2 a high pill burden, 
and overlapping side effects3 when three antiretro-
viral agents are added to the standard four antitu-
berculosis drugs. These challenges may result in 
interruption or discontinuation of treatment for the 
acquired immunodeficiency syndrome (AIDS) or 
tuberculosis, which can lead to drug resistance and 
potentially limit future therapeutic options,4,5 but 
the disadvantages must be weighed against the risk 
of increased mortality early in the treatment of 
tuberculosis.
The Starting Antiretroviral Therapy at Three 
Points in Tuberculosis (SAPIT) trial6 was designed 
to determine the clinical consequences of the time 
to the start of ART in patients with HIV infection 
and tuberculosis. We previously reported that in-
tegrating ART with tuberculosis treatment reduc-
es mortality.6 Here, we report on the initiation of 
ART at two points during tuberculosis treatment.
Me thods
Study Design, Patients, and Procedures
We conducted a prospective, open-label, random-
ized trial in South Africa. A total of 642 ambulatory 
patients with both pulmonary tuberculosis and 
HIV infection, 18 years of age or older, were en-
rolled after providing written informed consent.
The diagnosis of pulmonary tuberculosis was 
confirmed by a positive sputum smear for acid-
fast bacilli. HIV infection was confirmed by two 
rapid screening tests for HIV. All patients had a 
CD4+ T-cell count of less than 500 per cubic mil-
limeter at screening and were started on a stan-
dard tuberculosis treatment regimen.7 All pa-
tients with a first episode of tuberculosis were 
treated with a fixed combination of rifampin, iso-
niazid, ethambutol, and pyrazinamide, with doses 
determined according to pretreatment weight, for 
2 months (intensive phase) and a subsequent fixed 
combination of isoniazid and rifampicin for 
4 months (continuation phase). Patients who had 
previously received treatment for tuberculosis re-
ceived a 60-day intensive regimen that included 
streptomycin, followed by a 100-day continuation 
regimen.
The once-daily ART regimen consisted of en-
teric-coated didanosine (250 mg if the patient’s 
weight was <60 kg and 400 mg if the weight was 
≥60 kg), lamivudine (300 mg), and efavirenz 
(600 mg). Adherence to ART was assessed month-
ly by means of pill counts. Notwithstanding the 
study-group assignments, patients could be started 
on ART at any time at the discretion of the study 
clinicians or the patients’ primary care physicians. 
Details of the study design and procedures have 
been described previously6 and are provided in the 
protocol and Supplementary Appendix, available 
with the full text of this article at NEJM.org.
The outcome of the sequential-therapy group 
(ART initiated after the completion of tuberculosis 
treatment) has been reported previously.6 The 
analysis reported here includes complete follow-up 
data on the 214 patients in the early integrated-
therapy group (ART initiated within 4 weeks after 
the start of tuberculosis treatment) and the 215 
patients in the late integrated-therapy group (ART 
initiated within 4 weeks after completion of the 
intensive phase of tuberculosis treatment).
Study Oversight
The trial was approved by the Biomedical Research 
Ethics Committee at the University of KwaZulu-
Natal and by the Medicines Control Council of the 
South African government. Study data were re-
viewed periodically by a data and safety monitoring 
committee. All authors vouch for the completeness 
and accuracy of the data and analyses presented.
Statistical Analysis
All analyses were performed in the intention-to-
treat population. The primary outcome, the inci-
dence rate of AIDS or death, was analyzed with the 
use of Kaplan–Meier curves. The duration of time 
in the study was calculated as the time from ran-
domization to death or AIDS-defining illness, 
withdrawal from the study, or 18 months after 
randomization, whichever occurred first. Poisson 
approximations were used to calculate confidence 
intervals for the incidence-rate ratios. Cox propor-
tional-hazards regression was used to adjust for 
confounding variables. Fisher’s exact test was used 
for the analysis of categorical data, and unpaired 
t-tests or the Wilcoxon two-sample test was used 
The New England Journal of Medicine 
Downloaded from nejm.org on October 20, 2011. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 365;16 nejm.org october 20, 20111494
for the analysis of continuous data. Interactions be-
tween therapy group and CD4+ T-cell count were 
evaluated by fitting a proportional-hazards model 
with therapy group, CD4+ T-cell count, and the 




A total of 429 patients were enrolled in the two 
integrated-therapy groups: 214 were randomly as-
signed to receive early integrated therapy (hereafter 
referred to as the earlier-ART group), and 215 were 
assigned to receive late integrated therapy (hereaf-
ter referred to as the later-ART group). At baseline, 
the two groups had similar demographic and clin-
ical characteristics (Table 1). The median CD4+ 
T-cell count was 150 per cubic millimeter, and 
the median viral load was 161,000 copies per mil-
liliter. The median duration of follow-up in the 
trial was 17.7 months (interquartile range, 14.0 to 
17.8). At study completion, the retention rates were 
76.9% and 71.5% in the earlier-ART and later-
ART groups, respectively (information on reten-
tion and causes of death is provided in the Sup-
plementary Appendix).
Initiation of art
Among patients who completed tuberculosis ther-
apy, the median treatment duration was 210 days 
in the earlier-ART group (207 participants) and 
203 days in the later-ART group (210 participants). 
A total of 92.5% of the patients in the earlier-ART 
group (198 of 214) and 76.3% in the later-ART 
group (164 of 215) started ART during the study 
(P<0.001). The longer period from randomization 
to the initiation of ART in the later-ART group 
meant that more patients in this group were lost to 
follow-up, withdrew, or died before the start of 
ART, as compared with the earlier-ART group (Fig. 
1). However, there were no significant differences 
between the earlier-ART and later-ART groups in 
the overall rates of loss to follow-up (12.1% [26 of 
214] and 15.8% [34 of 215], P = 0.33) and withdraw-
al (9.3% [20 of 214] and 10.7% [23 of 215], P = 0.75).
The 198 patients in the earlier-ART group who 
started ART did so at a median of 21 days (inter-
quartile range, 15 to 29) after the initiation of tu-
berculosis therapy. Of the 33 patients who started 
ART after the 4-week window, 9 missed the 
study-clinic visit for the initiation of ART, 8 had 
abnormal liver function, 2 had other laboratory 
abnormalities, 4 declined ART, and 10 had clinical 
conditions that precluded ART initiation.
The 164 patients in the later-ART group who 
started ART did so at a median of 97 days (inter-
quartile range, 77 to 126) after the initiation of 
tuberculosis therapy. One patient started ART dur-
ing the intensive phase of tuberculosis treatment. 
Of the 47 patients who started ART more than 
4 weeks after completion of the intensive phase 
of tuberculosis treatment, 29 missed the study-
clinic visit for the initiation of ART, 1 had abnor-
mal liver function, 6 declined ART, and 11 had 
clinical conditions that precluded ART initiation.
Incidence Rates of AIDS or Death
The incidence rate of AIDS or death was 6.9 cases 
per 100 person-years in the earlier-ART group (18 
cases) as compared with 7.8 per 100 person-years 
in the later-ART group (19 cases) (incidence-rate 
ratio, 0.89; 95% confidence interval [CI], 0.44 to 
1.79; P = 0.73). After adjustment for baseline World 
Health Organization (WHO) disease stage (stage 4 
vs. stage 3), age, sex, history of tuberculosis (yes or 
no), presence or absence of extrapulmonary tuber-
culosis, and baseline CD4+ T-cell count and HIV 
RNA level, the hazard ratio with earlier ART was 
0.86 (95% CI, 0.42 to 1.85; P = 0.72). The probability 
of observing 18 AIDS cases or deaths in the earlier-
ART group and 19 cases in the later-ART group was 
5.6%, 1.9%, and 0.4%, if the true difference in AIDS 
cases or deaths between the groups was 40%, 50%, 
and 60%, respectively. In a sensitivity analysis in 
which all participants lost to follow-up were classi-
fied as having died, the incidence was 17.0 cases per 
100 person-years (95% CI, 12.3 to 22.8) in the ear-
lier-ART group and 21.7 per 100 person years (95% 
CI, 16.3 to 28.4) in the later-ART group (incidence-
rate ratio, 0.78; 95% CI, 0.51 to 1.19; P = 0.23).
Incidence Rates of AIDS or Death According to 
CD4+ T-Cell Count
A significant interaction between therapy group 
and CD4+ T-cell count was observed for AIDS or 
death (P = 0.03), indicating heterogeneity across the 
two CD4+ strata in the effect of time to initiation of 
ART on the incidence of AIDS or death. The inci-
dence rates of AIDS or death among the 72 patients 
with CD4+ T-cell counts of less than 50 per cubic 
millimeter were 8.5 cases per 100 person-years 
(95% CI, 2.3 to 21.9) in the earlier-ART group as 
compared with 26.3 per 100 person-years (95% CI, 
12.6 to 48.4) in the later-ART group (incidence-rate 
ratio, 0.32; 95% CI, 0.07 to 1.13; P = 0.06) (Table 2 
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and Fig. 2). Among the 357 patients with baseline 
CD4+ T-cell counts of 50 per cubic millimeter or 
higher, the incidence rates of AIDS or death were 
6.6 cases per 100 person-years (95% CI, 3.6 to 11.0) 
and 4.4 per 100 person-years (95% CI, 2.0 to 8.3) 
in the earlier-ART and later-ART groups, respec-
tively (incidence-rate ratio, 1.51; 95% CI, 0.61 to 
3.95; P = 0.34).
IRIS
Among patients with a CD4+ T-cell count of less 
than 50 per cubic millimeter, the incidence of IRIS 
was 4.7 times as high in the earlier-ART group as 
in the later-ART group (P = 0.01) (Table 2). Among 
patients with a CD4+ T-cell count of 50 per cubic 
millimeter or higher, the incidence of IRIS was 
2.2 times as high in the earlier-ART group as in the 







(N = 429) P Value
Age — yr 0.75
Mean 34.3±8.0 34.5±8.7 34.4±8.4
Range 19–63 21–72 19–72
Male sex — no. (%) 97 (45.3) 112 (52.1) 209 (48.7) 0.18
Educational level — no. (%)† 0.23
Primary school or less 43 (20.2) 49 (22.9) 92 (21.5)
Some secondary school 97 (45.5) 108 (50.5) 205 (48.0)
Completed secondary school 73 (34.3) 57 (26.6) 130 (30.4)
Employed — no. (%) 135 (63.1) 117 (54.4) 252 (58.7) 0.08
History of tuberculosis — no. (%) 80 (37.4) 68 (31.6) 148 (34.5) 0.22
Karnofsky performance score — no. (%)‡ 0.84
90 or 100 123 (57.5) 128 (59.5) 251 (58.5)
70 or 80 86 (40.2) 81 (37.7) 167 (38.9)
<70 5 (2.3) 6 (2.8) 11 (2.6)
WHO stage 4 HIV infection — no. (%)§ 14 (6.5) 11 (5.1) 25 (5.8) 0.54
Presence of extrapulmonary tuberculosis — no. (%) 10 (4.7) 9 (4.2) 19 (4.4) 0.82
Resistance to tuberculosis drugs — no./total no. (%)
Isoniazid 13/102 (12.7) 5/101 (5.0) 18/203 (8.9) 0.08
Rifampin 8/102 (7.8) 4/101 (4.0) 12/203 (5.9) 0.37
Ethambutol 1/101 (1.0) 0/100 (0.0) 1/201 (0.5) 1.00
Multidrug resistance 6/102 (5.9) 3/101 (3.0) 9/203 (4.4) 0.50
CD4+ T-cell count — cells/mm3¶ 0.93
Median 154 149 150
Interquartile range 75–261 77–244 77–254
Viral load — log10 copies/ml∥ 0.53
Median 5.1 5.2 5.2
Interquartile range 4.5–5.6 4.5–5.6 4.5–5.6
No. of days of tuberculosis therapy at randomization 0.49
Median 9 9 9
Interquartile range 7–13 7–14 7–14
* Plus–minus values are means ±SD.
† Data on educational level were not available for one patient in each group.
‡ The Karnofsky performance score is a measure of the patient’s general condition and degree of autonomy on a scale 
ranging from 0 to 100, with lower numbers indicating poorer function.
§ The remainder of patients had stage 3 infection, according to criteria of the World Health Organization (WHO).
¶ Patients underwent randomization on the basis of the CD4+ T-cell count at screening (criterion for study enrollment, 
<500 per cubic millimeter). However, for 16 patients, the CD4+ T-cell count at enrollment was 500 per cubic millimeter 
or higher.
∥ Data on the viral load at baseline were not available for 16 patients in each group.
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642 Underwent randomization
1331 Were screened
3301 Patients were assessed for eligibility
1970 Were excluded
794 Were HIV-negative
627 Declined HIV testing
349 Did not return for screening visit
200 Had other reasons
689 Were excluded
130 Did not return for randomization
101 Responded after enrollment window
100 Returned for enrollment when enrollment 
was not open
91 Did not have confirmed positive smear 
for acid-fast bacilli
55 Had CD4+ T-cell count ≥500/mm3
44 Declined participation
38 Had medical reasons
17 Planned to relocate
17 Had practical reasons
16 Declined ART
13 Were receiving ART
12 Had no sputum test
10 Died
6 Were not receiving tuberculosis treatment
3 Were pregnant or planned pregnancy
36 Had other reasons
214 Were assigned to earlier
integrated-treatment group
215 Were assigned to later
integrated-treatment group
16 (7.5%) Did not start ART
4 (1.9%) Died
6 (2.8%) Were lost to follow-up
6 (2.8%) Were withdrawn
4 (1.9%) Requested withdrawal
1 (0.5%) Relocated
1 (0.5%) Could not attend visits
51 (23.7%) Did not start ART
8 (3.7%) Died
22 (10.2%) Were lost to follow-up
5 (2.3%) Completed study with-
out initiating ART
16 (7.4%) Were withdrawn
6 (2.8%) Requested withdrawal
6 (2.8%) Relocated
4 (1.9%) Were unable to comply
with protocol
213 Were assigned to sequential-
treatment group (stopped early)
198 Started ART 164 Started ART
45 (22.7%) Did not complete study
11 (5.6%) Died
20 (10.1%) Were lost to follow-up
14 (7.1%) Were withdrawn
5 (2.5%) Requested withdrawal
8 (4.0%) Relocated
1 (0.5%) Was unable to comply 
with protocol
153 Completed study 138 Completed study
26 (15.9%) Did not complete study
7 (4.3%) Died
12 (7.3%) Were lost to follow-up
7 (4.3%) Were withdrawn
2 (1.2%) Requested withdrawal
4 (2.4%) Relocated
1 (0.6%) Was unable to comply
with protocol
Figure 1. Enrollment and Outcomes.
Loss to follow-up was defined as no visit during the previous 4 months. ART denotes antiretroviral therapy.
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later-ART group (P = 0.02) (Table 2, and Table 1 in 
the Supplementary Appendix). No significant inter-
action was observed that would indicate a lack of 
heterogeneity across the two CD4+ strata in the ef-
fect of time to the initiation of ART on the inci-
dence of IRIS. The median time from the initiation 
of ART to the development of IRIS was 15.0 days 
(interquartile range, 7 to 30) in the earlier-ART 
group and 15.5 days (interquartile range, 14 to 
28) in the later-ART group.
Adherence to Therapy and Switching  
of Drugs
Nineteen patients in each of the two study groups 
were considered to have defaulted tuberculosis 
therapy (8.9% and 8.8% in the earlier-ART and 
later-ART groups, respectively), either if they chose 
to interrupt therapy or if they did not attend the 
clinic for any further scheduled study visits before 
treatment completion. According to monthly pill 
counts, patients in the earlier-ART and later-ART 
groups took 98.0% and 98.8% of their assigned 
antiretroviral tablets, respectively, during the trial.
Ten patients in the earlier-ART group and one 
patient in the later-ART group needed to switch 
antiretroviral drugs because of adverse events 
(P = 0.006). Among patients with CD4+ T-cell 
counts of 50 per cubic millimeter or higher, seven 
patients in the earlier-ART group and one patient 
in the later-ART group switched antiretroviral 
drugs (P = 0.04).
A total of 15 patients (6 in the earlier-ART 
group and 9 in the later-ART group) changed their 
ART regimens because of virologic failure (defined 
as a viral load >1000 copies per milliliter on two 
occasions at least 4 weeks apart). The instances of 
drug switching occurred an average of 9.0 months 
(95% CI, 5.9 to 12.2) and 11.9 months (95% CI, 9.1 
to 14.6) after the initiation of ART in the earlier-
ART and later-ART groups, respectively (P = 0.18).
Outcomes of Tuberculosis and HIV Treatment
There was no significant difference between the 
study groups in resistance to tuberculosis drugs 
at baseline (Table 1). Outcomes of tuberculosis 
treatment did not differ significantly between the 
groups (Table 3, and Table 2 in the Supplementary 
Appendix); this finding did not change after adjust-
ment for the presence or absence of multidrug re-
sistance. At 6 and 12 months after randomization, 
the proportions of participants with a suppressed 
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the earlier-ART and later-ART groups. However, the 
mean increases from baseline in the CD4+ T-cell 
count at 12 and 18 months were significantly high-
er in the earlier-ART group than in the later-ART 
group (Table 4).
Adverse Events
Grade 3 or 4 non-IRIS adverse events occurred in 
112 patients in the earlier-ART group and in 107 
patients in the later-ART group (42.8 and 42.6 
events per 100 person-years, respectively; P = 0.98); 
serious adverse events occurred in 56 and 50 pa-
tients in the respective groups. Table 3 in the Sup-
plementary Appendix provides details of the ad-
verse events.
Discussion
Overall, the rates of AIDS or death did not differ 
significantly between the patients who received 
early integrated ART and those who received late 
integrated ART, but the earlier-ART group had 
higher rates of IRIS and switching of antiretroviral 
drugs because of adverse events. However, the find-
ings in severely immunocompromised patients dif-
fered. In the subgroup of patients with CD4+ T-cell 
counts of less than 50 per cubic millimeter, earlier 
ART was associated with a rate of AIDS or death 
that was about two thirds lower than the rate with 
later ART; this benefit outweighs the significantly 
higher rates of IRIS (incidence-rate ratio, 4.7) and 
of switching of antiretroviral drugs associated with 
earlier ART. For patients with CD4+ T-cell counts of 
less than 50 per cubic millimeter, our findings 
support the 2009 WHO recommendation8 to start 
ART as soon as possible after the initiation of tu-
berculosis treatment.
Our findings suggest a different approach for 
patients with tuberculosis and HIV who have a 
CD4+ T-cell count of 50 per cubic millimeter or 
higher. The initiation of ART during the first 
4 weeks of the continuation phase of tuberculosis 
treatment versus initiation during the first 4 weeks 
of the intensive phase of tuberculosis treatment 
was not associated with an increased risk of AIDS 
or death but was associated with about half the 
risk of IRIS and a significantly lower risk of the 
need to switch antiretroviral drugs because of ad-
verse events. Thus, for this subgroup of patients, 
ART can be deferred until the start of the con-
tinuation phase of tuberculosis treatment. How-
ever, a longer delay should be avoided, in light of 
our previous finding that sequential ART (after 
the completion of tuberculosis treatment) was 
associated with 56% higher mortality, as compared 
with its initiation during tuberculosis treatment.6
Some limitations of our study need to be con-
sidered. First, the observed 68% lower rate of AIDS 
or death among severely immunocompromised 
patients as compared with the rate among other 
patients (incidence-rate ratio, 0.32), although sub-
stantial, was not significant (P = 0.06). However, it 
is unlikely that this finding was due to chance, 
because a survival benefit in severely immunocom-
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Figure 2. Kaplan–Meier Curves for Survival without an AIDS-Defining Illness.
Panel A shows the data for patients with a CD4+ T-cell count of less than 
50 per cubic millimeter, and Panel B shows the data for patients with higher 
CD4+ T-cell counts. TB denotes tuberculosis.
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bodian Early versus Late Introduction of Antiretro-
virals study (CAMELIA; ClinicalTrials.gov number, 
NCT01300481). In the Cambodian study, among 
patients coinfected with tuberculosis and HIV who 
had a median CD4+ T-cell count of 25 per cubic 
millimeter, those who started ART 2 weeks after 
the initiation of tuberculosis treatment had 38% 
lower mortality than those who waited 8 weeks 
to start ART (P = 0.006).9 Among patients with 
CD4+ T-cell counts below 50 per cubic millimeter 
in the AIDS Clinical Trials Group Study A5221 
(NCT00108862), 15.5% of patients in the earlier-
ART group versus 26.6% in the later-ART group 
had an AIDS-defining illness or died (95% CI, 
1.5 to 20.5; P = 0.02).10
Second, the lack of a survival benefit in pa-
tients with CD4+ T-cell counts of 50 per cubic 
millimeter or higher may be due to the sample 
size (357 patients) and the small number of 
deaths observed. There would be only a 9.2% 
probability of observing these rates of death if 
the true difference in mortality between the 
earlier-ART and later-ART groups was 34% or 
greater. Furthermore, the limited observational 
data available show similar trends. In a pilot 
study of the initiation of ART involving 70 pa-
tients with a median CD4+ T-cell count of 103 
per cubic millimeter, there were 2 deaths in the 
early-therapy group (within 2 weeks after the 
start of tuberculosis treatment) versus 1 death in 
the delayed-therapy group (8 weeks after the start 
of tuberculosis treatment) (P = 0.601).11
Third, inaccuracies in the diagnosis of IRIS, and 
therefore in the reported incidence of the syn-
drome, may have affected the study outcome. 
The incidence rate of 14.2% observed in this study 
is consistent with findings from other South Afri-
can studies. In one study of patients coinfected 
with tuberculosis and HIV, the incidence of IRIS 
was 12% overall, yet 32% of patients who started 
ART within 2 months after receiving a diagnosis 
of tuberculosis had an IRIS event.12 The risk of 
IRIS remained elevated if ART was started within 
3 months after the initiation of tuberculosis treat-
ment, but it was highest during the first month 
of tuberculosis treatment. A retrospective analysis 
of 627 patients from India showed that 7.6% of 
patients with tuberculosis (18 of 237) had para-
doxical tuberculosis-associated IRIS, and 3.1% of 
patients without tuberculosis (12 of 390) had 
IRIS associated with ART.13 A low CD4+ T-cell 
count at baseline and early initiation of ART 
Table 3. Clinical Outcomes of Tuberculosis Treatment.
Outcome
Baseline CD4+ T-Cell Count 
<50/mm3










number of patients (percent)
Tuberculosis cured* 23 (62) 24 (69) 108 (61) 114 (63)
Tuberculosis treatment successfully completed† 8 (22) 4 (11) 32 (18) 34 (19)
Treatment successful‡ 31 (84) 28 (80) 140 (79) 148 (82)
Patient died before tuberculosis treatment  
completed
3 (8) 4 (11) 11 (6) 7 (4)
Treatment interruption 0 1 (3) 5 (3) 3 (2)
Treatment failure with first-line regimen§ 1 (3) 0 5 (3) 2 (1)
Patient lost to follow-up before tuberculosis  
treatment completed
1 (3) 1 (3) 12 (7) 15 (8)
Patient transferred to other clinic, tuberculosis 
treatment outcome not known
1 (3) 1 (3) 4 (2) 5 (3)
* Tuberculosis cure was defined in accordance with the South African National Tuberculosis Control Programme Practical 
Guidelines 2004, which states, “Patient who is smear-negative at, or one month prior to, the completion of treatment 
and also on at least one previous occasion.” Most study patients were unable to produce sputum after the first few 
months of tuberculosis treatment, making demonstration of a cure difficult.
† Successful completion of treatment was defined as the use of more than 85% of the prescribed medication.
‡ Treatment success was defined as tuberculosis cure and successful completion of tuberculosis treatment.
§ Treatment failure was defined as a positive smear or culture for Mycobacterium tuberculosis that was obtained at least 
5 months after the initiation of tuberculosis therapy.
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were significantly associated with paradoxical 
tuberculosis-associated IRIS.
The rates of adverse events in the earlier-ART 
and later-ART groups were not substantially differ-
ent. Published data on additive treatment-related 
toxic effects in patients receiving treatment for 
both tuberculosis and HIV infection are limited. A 
retrospective study in India showed that concomi-
tant use of ART and tuberculosis treatment was a 
predictor of adverse events (odds ratio, 1.88).14 
Furthermore, a study from Thailand showed that 
44.6% of patients receiving treatment for tubercu-
losis and HIV had adverse events due to antituber-
culosis drugs or ART.15 Of these patients, 66% had 
adverse events within the first 2 months after the 
start of tuberculosis treatment, and 76.8% had to 
stop or change either antituberculosis or antiretro-
viral drugs. In contrast, a retrospective study from 
South Africa showed that the occurrence of serious 
adverse events was unrelated to the use of antiret-
roviral drugs in patients with tuberculosis.16
In our study, there were no significant differ-
ences between the earlier-ART and later-ART 
groups in the outcomes of tuberculosis treatment 
Table 4. Clinical Outcomes of ART.
Outcome and Baseline CD4+ T-Cell Count Earlier ART Later ART P Value
no./total no. % (95% CI) no./total no. % (95% CI)
Viral load <400 copies/ml
At 6 mo after initiation of ART
Overall 161/179 89.9 (84.3–93.8) 166/179 92.7 (87.6–95.9) 0.45
CD4+ count <50/mm3 30/34 88.2 (71.6–96.2) 32/35 91.4 (75.8–97.8) 0.71
CD4+ count ≥50/mm3 131/145 90.3 (84.0–94.4) 134/144 93.1 (87.3–96.4) 0.52
At 12 mo after randomization
Overall 147/159 92.5 (86.9–95.9) 130/147 88.4 (81.9–92.9) 0.25
CD4+ count <50/mm3 30/32 93.8 (77.8–98.9) 23/27 85.2 (65.4–95.1) 0.40
CD4+ count ≥50/mm3 117/127 92.1 (85.6–96.0) 107/120 89.2 (81.9–93.9) 0.51
At 18 mo after randomization
Overall 144/153 94.1 (88.8–97.1) 135/143 94.4 (88.9–97.4) 1.00
CD4+ count <50/mm3 28/30 93.3 (76.5–98.8) 25/26 96.2 (78.4–99.8) 1.00









Mean increase in CD4+ count
At 6 mo after initiation of ART
Overall 178 132 (113–152) 179 132 (111–152) 0.95
CD4+ count <50/mm3 34 124 (94–154) 35 104 (83–124) 0.25
CD4+ count ≥50/mm3 144 134 (111–157) 144 138 (113–163) 0.82
At 12 mo after randomization
Overall 159 183 (162–204) 147 125 (105–145) 0.009
CD4+ count <50/mm3 32 170 (127–213) 27 111 (81–141) 0.03
CD4+ count ≥50/mm3 127 186 (163–210) 120 128 (104–152) 0.001
At 18 mo after randomization
Overall 152 217 (192–243) 142 172 (150–194) 0.009
CD4+ count <50/mm3 30 207 (166–248) 26 173 (134–212) 0.22
CD4+ count ≥50/mm3 122 220 (189–251) 116 172 (146–198) 0.02
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or in the proportion of participants with a sup-
pressed viral load. However, significant increases 
in the CD4+ T-cell count at 12 and 18 months were 
observed in the earlier-ART group, probably as a 
result of the longer duration of ART as compared 
with the duration in the later-ART group. This 
finding may have implications for longer-term 
survival, for which long-term follow-up would be 
needed.
These results of the SAPIT study further support 
the integration of treatment for tuberculosis and 
HIV infection. The current WHO recommendation 
to initiate ART as soon as possible after the start 
of tuberculosis treatment, regardless of the CD4+ 
T-cell count, may need to be revisited in view of the 
findings of this study. We found that early initia-
tion of ART in patients with CD4+ T-cell counts 
of less than 50 per cubic millimeter increased 
AIDS-free survival, whereas deferral of the initia-
tion of ART to the first 4 weeks of the continuation 
phase of tuberculosis therapy in those with higher 
CD4+ T-cell counts reduced the risks of IRIS and 
other adverse events related to ART without in-
creasing the risk of AIDS or death.
Presented in part at the 18th Conference on Retroviruses and 
Opportunistic Infections, Boston, February 27–March 2, 2011.
Supported by the U.S. President’s Emergency Plan for AIDS 
Relief; the Centre for the AIDS Programme of Research in South 
Africa (CAPRISA); the Global Fund to Fight AIDS, Tuberculosis, 
and Malaria; and the National Institutes of Health Comprehen-
sive International Program of Research on AIDS.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
We thank the patients for their participation in this study; 
Prof. Willem Sturm of the Nelson R. Mandela School of Medi-
cine for confirmatory tuberculosis testing; the management and 
staff of the Prince Cyril Zulu Communicable Disease Clinic, 
eThekwini Municipality, for support of the study; Drs. Gray 
Handley, Ed Tramont, Rod Hoff, Sandi Lehrman, and Richard 
Hafner of the Division of AIDS at the National Institutes of 
Health for study support; Drs. Gavin Churchyard, Douglas Tay-
lor, and Mark Weaver for serving on the data and safety monitor-
ing committee; members of the Community Advisory Board for 
their advice regarding the conduct of the trial; Ms. Nomapando 
Barnabas of the CAPRISA Community Programme for oversee-
ing community involvement in the trial; Ms. Natasha Samsunder 
and Mr. Keith Coetzee for laboratory analysis; Ms. Nonhlanhla 
Yende for statistical support; Ms. Irene van Middelkoop for data 
management; and all the other members of the SAPIT study 
team for their commitment to high-quality study conduct.
References
1. Fishman JE, Saraf-Lavi E, Narita M, 
Hollender ES, Ramsinghani R, Ashkin D. 
Pulmonary tuberculosis in AIDS partici-
pants: transient chest radiographic wors-
ening after initiation of antiretroviral 
therapy. AJR Am J Roentgenol 2000;174: 
43-9.
2. Chien JW, Johnson JL. Paradoxical re-
actions in HIV and pulmonary TB. Chest 
1998;114:933-6.
3. Girardi E, Palmieri F, Cingolani A, et 
al. Changing clinical presentation and sur-
vival in HIV-associated tuberculosis after 
highly active antiretroviral therapy. J Ac-
quir Immune Defic Syndr 2001;26:326-
31.
4. Lalloo UG. Efavirenz and nevirapine 
interactions with rifampicin: resolving the 
dilemmas? Clin Infect Dis 2009;48:1760-2.
5. Cohen K, Grant A, Dandara C, et al. 
Effect of rifampicin-based antitubercular 
therapy and the cytochrome P450 2B6 
516G>T polymorphism on efavirenz con-
centrations in adults in South Africa. An-
tivir Ther 2009;14:687-95.
6. Abdool Karim SS, Naidoo K, Grobler 
A, et al. Timing of initiation of antiretro-
viral drugs during tuberculosis therapy. 
N Engl J Med 2010;362:697-706.
7. The South African National Tuberculo-
sis Control Programme: practical guide-
lines 2004. Pretoria: South African De-
partment of Health, 2004.
8. Rapid advice: antiretroviral therapy for 
HIV infection in adults and adolescents. 
Geneva: World Health Organization, 2009.
9. Blanc F-X, Sok T, Laureillard D, et al. 
Earlier versus later start of antiretroviral 
therapy in HIV-infected adults with tuber-
culosis. N Engl J Med 2011;365:1471-81.
10. Havlir DV, Kendall MA, Ive P, et al. 
Timing of antiretroviral therapy for HIV-1 
infection and tuberculosis. N Engl J Med 
2011;365:1482-91.
11. Shao HJ, Crump JA, Ramadhani HO, 
et al. Early versus delayed fixed dose com-
bination abacavir/lamivudine/zidovudine 
in patients with HIV and tuberculosis in 
Tanzania. AIDS Res Hum Retroviruses 
2009;25:1277-85.
12. Lawn SD, Myer L, Bekker LG, Wood R. 
Tuberculosis-associated immune reconsti-
tution disease: incidence, risk factors and 
impact in an antiretroviral treatment ser-
vice in South Africa. AIDS 2007;21:335-41.
13. Sharma SK, Dhooria S, Barwad P, et al. 
A study of TB-associated immune recon-
stitution inflammatory syndrome using 
the consensus case-definition. Indian J 
Med Res 2010;131:804-8.
14. Dean GL, Edwards SG, Ives NJ, et al. 
Treatment of tuberculosis in HIV-infected 
persons in the era of highly active antiret-
roviral therapy. AIDS 2002;16:75-83.
15. Tansuphasawadikul S, Saito W, Kim J, 
et al. Outcomes in HIV-infected patients 
on antiretroviral therapy with tuberculo-
sis. Southeast Asian J Trop Med Public 
Health 2007;38:1053-60.
16. Marks DJ, Dheda K, Dawson R, Ain-
slie G, Miller RF. Adverse events to antitu-
berculosis therapy: influence of HIV and 
antiretroviral drugs. Int J STD AIDS 2009; 
20:339-45.
Copyright © 2011 Massachusetts Medical Society.
EARLY JOB ALERT SERVICE AVAILABLE AT THE NEJM CAREERCENTER
Register to receive weekly e-mail messages with the latest job openings  
that match your specialty, as well as preferred geographic region,  
practice setting, call schedule, and more. Visit the NEJM CareerCenter  
at NEJMjobs.org for more information.
The New England Journal of Medicine 
Downloaded from nejm.org on October 20, 2011. For personal use only. No other uses without permission. 
 Copyright © 2011 Massachusetts Medical Society. All rights reserved. 
